<div id="readability-page-1"><p>Corient Private Wealth LLC grew its stake in shares of  Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 129.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor  owned 11,825 shares of the medical research company's stock after acquiring an additional 6,669 shares during the quarter. Corient Private Wealth LLC's holdings in Charles River Laboratories International were worth $1,794,000 as of its most recent SEC filing.</p><ul><li>The 2 Worst Performing S&amp;P 500 Stocks YTD: Buy, Sell, or Avoid?</li></ul><p>A number of other institutional investors also recently bought and sold shares of the stock. Exchange Traded Concepts LLC increased its stake in  Charles River Laboratories International by 1.3% during the 2nd quarter. Exchange Traded Concepts LLC now owns 5,742 shares of the medical research company's stock valued at $871,000 after purchasing an additional 76 shares in the last quarter.  Brooklyn Investment Group grew its holdings in shares of  Charles River Laboratories International by 93.5% during the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock valued at $27,000 after buying an additional 86 shares during the last quarter.  DekaBank Deutsche Girozentrale increased its position in shares of  Charles River Laboratories International by 1.2% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,142 shares of the medical research company's stock valued at $1,072,000 after acquiring an additional 86 shares during the period.  WESCAP Management Group Inc. raised its stake in  Charles River Laboratories International by 3.8% in the 2nd quarter. WESCAP Management Group Inc. now owns 2,443 shares of the medical research company's stock worth $371,000 after acquiring an additional 89 shares during the last quarter.  Finally, State of New Jersey Common Pension Fund D lifted its position in  Charles River Laboratories International by 0.7% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 16,829 shares of the medical research company's stock worth $2,553,000 after acquiring an additional 109 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Charles River Laboratories International Stock Performance</h2><p>CRL opened at $202.99 on Wednesday. The firm has a fifty day moving average price of $181.14 and a 200 day moving average price of $166.54. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $204.47. The stock has a market cap of $9.99 billion, a P/E ratio of -130.12, a P/E/G ratio of 7.17 and a beta of 1.63. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10. </p><p>Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating analysts' consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The company had revenue of $1 billion during the quarter, compared to analysts' expectations of $990.43 million. During the same quarter in the previous year, the company earned $2.59 earnings per share. The firm's revenue for the quarter was down .5% on a year-over-year basis.  Equities research analysts anticipate that  Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year. </p><h2>Analyst Ratings Changes</h2><p>A number of research analysts have recently weighed in on CRL shares. Mizuho increased their price objective on Charles River Laboratories International from $174.00 to $200.00 and gave the company a &#34;neutral&#34; rating in a report on Thursday, December 18th. Robert W. Baird upgraded shares of Charles River Laboratories International from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and increased their price target for the stock from $178.00 to $199.00 in a report on Thursday, November 6th. Wall Street Zen raised shares of Charles River Laboratories International from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Sunday. Barclays upped their price objective on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the company an &#34;overweight&#34; rating in a report on Monday, December 15th. Finally, Morgan Stanley  set a $185.00 target price on shares of Charles River Laboratories International in a report on Monday, December 1st. One equities research analyst  has rated the stock with a Strong Buy rating, eleven have issued  a Buy rating, five have given a Hold rating and one  has issued  a Sell rating to the stock. According to data from MarketBeat.com, the company  has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $195.93.</p><p><b>Check Out Our Latest Analysis on CRL</b></p><h2>About Charles River Laboratories International</h2> (Free Report)<p>Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.  </p><p>Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.</p><h2>Read More</h2><ul><li>Five stocks we like better than Charles River Laboratories International</li><li>The boring AI play that could pay up to $4,290 monthly</li><li>ALERT: Drop these 5 stocks before January 2026!</li><li>Trump’s “real estate deal for America” explained</li><li>A month before the crash</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNSTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNSTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Charles River Laboratories International Right Now?</h2><p>Before you consider Charles River Laboratories International, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.</p><p>While Charles River Laboratories International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Corient Private Wealth LLC increased its stake in Charles River Laboratories International, Inc. by 129.3% during Q2, now holding 11,825 shares worth $1,794,000. Other institutional investors also adjusted their holdings. Charles River's stock opened at $202.99 with a market cap of $9.99 billion. The company reported Q3 earnings of $2.43 per share, beating estimates. Analysts have given mixed ratings, with some upgrading their price targets.</p>

Corient Private Wealth LLC Raises Holdings in Charles River Laboratories International, Inc. $CRL